Filing Flows › Comparisons › XFOR vs ELUT
X4 Pharmaceuticals vs Elutia: XFOR and ELUT compared
X4 Pharmaceuticals is the larger company: $2.8M of revenue in its latest quarter (Q3 2026) against $2.4M for Elutia (Q2 2026). X4 Pharmaceuticals is growing faster (+75% against -12% a year earlier). Elutia is more profitable, with an operating margin of -327.9% against -714.0%.
Where the money goes: XFOR and ELUT
X4 Pharmaceuticals (XFOR) · Q3 2026
X4 Pharmaceuticals, Q3 2026: revenue $2.8M (+75% year over year), operating margin -714.0%, net loss $20.2M, operating cash flow −$20.2M. The chart follows the revenue to costs, profit and cash.
Elutia (ELUT) · Q2 2026
Elutia, Q2 2026: revenue $2.4M (-12% year over year), operating margin -327.9%, net loss $7.6M, operating cash flow −$8.5M. The chart follows the revenue to costs, profit and cash.
| X4 Pharmaceuticals (XFOR) | Elutia (ELUT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $2.8M | $2.4M |
| Revenue growth, Y/Y | +75% | -12% |
| Operating margin | -714.0% | -327.9% |
| Net earnings | −$20.2M | −$7.6M |
| Net margin | -721.4% | -315.0% |
| Operating cash flow | −$20.2M | −$8.5M |
| Market value | $424M | — |
| P/E | 1.9× | — |
| Analysts’ mean target | $11.60 | — |
Questions
Which is bigger, X4 Pharmaceuticals or Elutia?
X4 Pharmaceuticals is the larger company: $2.8M of revenue in its latest quarter (Q3 2026) against $2.4M for Elutia (Q2 2026).
Is X4 Pharmaceuticals or Elutia growing faster?
X4 Pharmaceuticals is growing faster (+75% against -12% a year earlier).
Which is more profitable, X4 Pharmaceuticals or Elutia?
Elutia is more profitable, with an operating margin of -327.9% against -714.0%.
More: X4 Pharmaceuticals earnings · how X4 Pharmaceuticals makes money · Elutia earnings · how Elutia makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.